Időpont: 2022. március 21-24.

Helyszín: SZTE ÁOK Radiológiai Klinika, Semmelweis u. 6

Időpont: 2022. március 21-24

Helyszín: SZTE ÁOK Radiológiai Klinika, Semmelweis u. 6

A regisztráció az online felületen fog történni. A regisztrációt még nem nyitottuk meg!!!

Program (egyeztetés alatt):

Mellkasi és hasi CT-anatómiaCT-vizsgálat elve, MSCT, rekonstrukciós módszerekCT kontrasztanyagok, vizsgálati tecnikaHasi sérülésekAkut hasi kórképekVese, mellékveseGI tractus, CT-endoscopiaMáj, eperendszerCsont/ízületParenchymas tüdőbetegségekGócos tüdőbetegségekMediastinum CT-vizsgálataKardiológiai CT-vizsgálatokAkut mellkasi kórképekPancreas CT vizsgálataNeuro-anatómiaKözponti idegrendszeri sérülésekGerinc, gerincvelő betegségeiFejlődési rendellenességekIntracranialis daganatokCerebrovascularis kórképekIntracranialis gyulladások, meszesedések, neurodegenerációHibák, tévedések koponyavizsgálatok soránTesztvizsga, esetmegbeszélés

Főszervező: Dr. Kincses Zsigmond Tamás

Részvételi díj: részvételi díj: 50.000 Ft/fő

Kérjük, csatlakozzon az EPA online webináriumhoz, amely a nők mentális egészségének folyamatos szakmai fejlődését célozza pszichiáterek és pszichiátriai gyakornokok számára Európa-szerte.

A webinárért CPD/CME pontok kaphatóak.

Regisztráció és további információ ide kattintva található.

2022. március 10-12. között rendezik meg a XXVII. Debreceni Kardiológiai Napokat.

FONTOS VÁLTOZÁS!

A jelenleg is hatályban lévő 21/2021. (XI.14.) számú miniszteri utasítás értelmében, a DKN konferencia kizárólag ONLINE formában kerülhet megrendezésre.

A regisztrációs díj összege: bruttó 20.000 Ft.

Befizetési határidő: 2022. február 20.

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation